BRAIN AG sets IPO price range

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): IPO

2016-01-20 / 21:00
The issuer is solely responsible for the content of this announcement.


The information contained herein is not for publication, release or
distribution (directly or indirectly) in or into or to persons in the
United States of America, Canada, Japan and Australia or any other
jurisdiction in which publication, release or distribution would be


BRAIN AG sets IPO price range 

  - Price range at 9.00 to 12.00 Euros per BRAIN-share

  - Total offer volume of 36.2 million to 48.3 million Euros including

  - Public offer and subscription period to start on 21 January 2016,
    expected to end on 3 February 2016

  - Special tranche for retail investors of minimum 10 percent

  - Approved prospectus published on the BRAIN website today

Zwingenberg, January 20, 2016: B.R.A.I.N. Biotechnology Research and
Information Network AG ("BRAIN AG") in cooperation with its current
shareholders as well as ODDO Seydler as lead manager of the transaction has
determined the terms for its initial public offering ("IPO"). Accordingly,
the price range has been set at 9.00 to 12.00 Euros per share. The
subscription period for the public offer will start on 21 January 2016 and
is scheduled to end on 3 February 2016.

The final offer price will be determined based on a bookbuilding process.
Trading of the BRAIN AG shares under the ticker symbol BNN and the ISIN
DE0005203947 / WKN 520394 is set to begin on the regulated market (Prime
Standard segment) of the Frankfurt Stock Exchange on 9 February 2016.

The offer will consist of initial public offerings in Germany and Austria
as well as private placements in certain jurisdictions outside of these
countries and outside the United States of America. No less than 10 per
cent of the offer shares are reserved for and will be allocated to retail
investors. Starting on January 21, the offered BRAIN shares can be
subscribed via the XETRA subscription functionality of the Frankfurt Stock
Exchange, which can be accessed over the interested retail investor's
depositary / online bank. Selected retail investors (BRAIN employees and
MIG fund investors as well as GC Global Chance Fund investors and GA Asset
Fund investors) are given the opportunity to subscribe offer shares
directly via a subscription portal on the Company's website

"As a representative of the new 'bioeconomy' industry, we are addressing
aspects of high social relevance", said Dr Juergen Eck, CEO of BRAIN AG.
"Thanks to our solutions and products, industrial processes can become more
resource-efficient, more energy-efficient and more sustainable. Products
can be made healthier and more natural. Following our IPO, we will be able
to accelerate such product developments while unlocking further growth
potential. The Frankfurt Stock Exchange, which by the way allows us to
include retail investors into the IPO, gives us the optimal platform to
list on."

The offer will comprise of 3,500,000 newly issued shares from a capital
increase and up to 525,000 shares in connection with a potential
over-allotment. This is provided from the holdings of the long-standing and
main shareholder MP Beteiligungs-GmbH. If all offered shares, including the
possible over-allotment, are placed, BRAIN AG will have a free float of
24.5 per cent of the Company's share capitalpost IPO. Depending on the
final offer price, and assuming complete placement of all offer shares, the
offer volume will be between 31.5 million and 42.0 million Euros excluding
the possible over-allotment (i.e. proceeds received by the Company), or
between 36.2 million and 48.3 million Euros including the possible

BRAIN AG intends to use the proceeds from the IPO primarily to fund the
development of new products (enzymes, performance microorganisms and
bioactive compounds) and to enhance the marketing of its own product
pipeline. Some portion may also be dedicated to finance further
acquisitions, amongst other possible uses.

Detailed information on the IPO is contained in the BRAIN securities
prospectus, which has been approved by the German Federal Financial
Supervisory Authority (BaFin) today. It is now available, inter alia, on
the Company's website at

ODDO SEYDLER Bank AG is acting as Sole Global Coordinator and Bookrunner in
the transaction. Blaettchen Financial Advisory GmbH is supporting the
Company as IPO consultant.


About BRAIN 

BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at


Biotechnology Research
And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11


This document and the information contained herein are for information
purposes only. This press release does not constitute an offer to sell, or
the solicitation of an offer to buy or subscribe for securities. A public
offer in the Federal Republic of Germany and in the Republic of Austria
will be made exclusively by means of and on the basis of an
English-language prospectus together with a German-language translation of
the summary. The prospectus will be published on the website of the Company
and will be also available in printed form free of charge from the Company
(Fax +49-6251-9331-11) and from ODDO SEYDLER BANK AG (Fax

This press release does not constitute an offer to sell, or the
solicitation of an offer to buy or subscribe for securities in or into the
United States of America, Australia, Canada or Japan or to other
jurisdictions in which publication, release or distribution would be
unlawful. Any securities referred to herein have not been, and will not be,
registered under the U.S. Securities Act of 1933, as amended ("U.S.
Securities Act"). Such securities may not be offered, sold or delivered
within the United States absent from registration under or an applicable
exemption from the registration requirements of the U.S. Securities Act.
Neither BRAIN AG nor any of its shareholders intends to register the
securities referred to in this press release in the United States. The
securities referred to in this press release have not been, and will not
be, registered under the applicable securities laws of Australia, Canada or
Japan. Subject to certain exceptions, the securities may not be offered or
sold in Australia, Canada or Japan or to, or for the account or benefit of,
any national, resident or citizen of Australia, Canada or Japan. There will
be no public offering of securities in the United States or anywhere
outside of the Federal Republic of Germany and the Republic of Austria.

This press release does not constitute an offer document or an offer of
transferable securities to the public in the United Kingdom to which
Section 85 of the U.K. Financial Services and Markets Act 2000 applies and
should not be considered as a recommendation that any person should
subscribe for or purchase any securities as part of the transaction. This
press release is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) to investment
professionals falling within Section 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order")
or (iii) high net worth entities, unincorporated associations and other
persons or entities falling within Section 49 (2), (a) to (d) of the Order
(all such persons together being referred to as "relevant persons"). This
press release or its contents must not be acted or relied on by persons who
are not relevant persons. Any investment or investment activity to which
this press release relates is available only to relevant persons and will
be engaged in only with relevant persons. This release (or parts thereof)
may not be published, reproduced, distributed or made available to third
parties in any other way without the prior consent of BRAIN AG.

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any
forward-looking statements.


2016-01-20 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at and


Share this page